Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

98 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study.
Meca-Lallana JE, de Mingo-Casado P, Amorin-Díaz M, Martínez-Navarro ML, Barreiro AF. Meca-Lallana JE, et al. Clin Ther. 2010 Jun;32(6):1061-6. doi: 10.1016/j.clinthera.2010.06.005. Clin Ther. 2010. PMID: 20637960 Clinical Trial.
Placebo-controlled trial of oral laquinimod for multiple sclerosis.
Comi G, Jeffery D, Kappos L, Montalban X, Boyko A, Rocca MA, Filippi M; ALLEGRO Study Group. Comi G, et al. N Engl J Med. 2012 Mar 15;366(11):1000-9. doi: 10.1056/NEJMoa1104318. N Engl J Med. 2012. PMID: 22417253 Free article. Clinical Trial.
Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practice.
Coyle PK, Khatri B, Edwards KR, Meca-Lallana JE, Cavalier S, Rufi P, Benamor M, Thangavelu K, Robinson M, Gold R; Teri-PRO Trial Group. Coyle PK, et al. Mult Scler Relat Disord. 2018 Nov;26:211-218. doi: 10.1016/j.msard.2018.09.017. Epub 2018 Sep 15. Mult Scler Relat Disord. 2018. PMID: 30273841 Free article. Clinical Trial.
Development and validation of a brief electronic screening test for cognitive impairment in multiple sclerosis (SCI-MS Test).
Meca-Lallana JE, Prieto-González JM, Jimenez-Veiga J, Carreón-Guarnizo E, Jiménez-Martín I, Hernández-Clares R, Sistiaga-Berrondo A, Carles-Dies R, García-Molina E, Cerdán-Sánchez M, Costa-Arpín E, Croitoru I, Castillo-Triviño T, Iniesta-Martinez F, García-Pérez E, Olascoaga-Urtaza J. Meca-Lallana JE, et al. Mult Scler Relat Disord. 2019 Feb;28:50-56. doi: 10.1016/j.msard.2018.12.003. Epub 2018 Dec 3. Mult Scler Relat Disord. 2019. PMID: 30553169
Prevention of rebound effect after natalizumab withdrawal in multiple sclerosis. Study of two high-dose methylprednisolone schedules.
Fuentes-Rumí L, Hernández-Clares R, Carreón-Guarnizo E, Valero-López G, Iniesta-Martinez F, Cabrera-Maqueda JM, León-Hernández A, Zamarro-Parra J, Morales-Ortiz A, Meca-Lallana JE. Fuentes-Rumí L, et al. Mult Scler Relat Disord. 2020 Sep;44:102311. doi: 10.1016/j.msard.2020.102311. Epub 2020 Jun 20. Mult Scler Relat Disord. 2020. PMID: 32593958
98 results